Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?

Area of Science:

• Pediatric Hematology
• Immunology
• Pharmacology

Background:

• Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
• Anti-D immunoglobulin is a treatment option for ITP, but its safety and efficacy in pediatric patients require further evaluation.

Purpose of the Study:

• To assess the efficacy and safety of repeated anti-D administration for pediatric ITP.
• To evaluate the side effect profile of anti-D in children with ITP.

Main Methods:

• Retrospective analysis of patient records from a large pediatric hematology center (1995-2015).
• Inclusion of children aged 4 months to 18 years treated for ITP with anti-D.
• Data extraction included demographic, clinical, adverse events, and therapy response (platelet count >30 x 10(9)/L).

Main Results:

• Thirty-six pediatric patients received 170 treatments of anti-D (75 μg/kg).
• Minimal adverse events reported: fever (3.5%), vomiting (2.9%), headaches (1.7%).
• Average time to platelet count >30 x 10(9)/L was 2.3 days (median 1 day); no life-threatening events occurred.

Conclusions:

• Repeated anti-D therapy is a safe and effective treatment for carefully selected pediatric ITP patients.
• The observed adverse events were minimal, contrasting with potential risks in elderly populations.
• Anti-D offers a viable therapeutic option for pediatric ITP, demonstrating rapid platelet count improvement.